37.03
1.94 (5.53%)
| Previous Close | 35.09 |
| Open | 34.82 |
| Volume | 1,241,666 |
| Avg. Volume (3M) | 1,033,895 |
| Market Cap | 3,246,287,104 |
| Price / Earnings (Forward) | 4.65 |
| Price / Sales | 14.71 |
| Price / Book | 2.88 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -5,147.81% |
| Diluted EPS (TTM) | -3.65 |
| Quarterly Revenue Growth (YOY) | 78.50% |
| Total Debt/Equity (MRQ) | 2.54% |
| Current Ratio (MRQ) | 13.92 |
| Operating Cash Flow (TTM) | -264.11 M |
| Levered Free Cash Flow (TTM) | -164.58 M |
| Return on Assets (TTM) | -21.84% |
| Return on Equity (TTM) | -31.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | IDEAYA Biosciences, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.25 |
|
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.90% |
| % Held by Institutions | 117.09% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 79.00 (JP Morgan, 113.34%) | Buy |
| Median | 50.00 (35.03%) | |
| Low | 45.00 (RBC Capital, 21.52%) | Buy |
| Average | 56.00 (51.23%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 34.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 21 Jan 2026 | 45.00 (21.52%) | Buy | 35.84 |
| UBS | 07 Jan 2026 | 50.00 (35.03%) | Buy | 37.86 |
| Truist Securities | 06 Jan 2026 | 60.00 (62.03%) | Buy | 36.31 |
| 24 Nov 2025 | 59.00 (59.33%) | Buy | 34.67 | |
| Mizuho | 11 Nov 2025 | 46.00 (24.22%) | Buy | 32.01 |
| JP Morgan | 23 Oct 2025 | 79.00 (113.34%) | Buy | 28.42 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |